LMPG: Practice Guidelines And Recommendations For Use Of Tumor Markers In The Clinic
 (Draft Guidelines - Second Posting)

Table of Contents - PDF Document Format
(Right click link to save file to your computer)

Section 1: Foreword and introduction (42 kb)

Section 2: Quality Requirements: Includes a summary of recommendations of the different sub-committees. (139 kb)

Section 3
3A: Use of Tumor Markers in Testicular Cancer (201 kb)

3B: Use of Tumor Markers in Prostate Cancer (227 kb)

3C: Use of Tumor Markers in Colorectal Cancer (154 kb)

3D: Use of Tumor Markers in Primary Liver Cancer (269 kb)

3E: Use of Tumor Markers in Ovarian Cancer (125 kb)

3F: Use of Tumor Markers in Breast Cancer (158 kb)

3G: Use of Tumor Markers in Gastric Cancer (114 kb)

3H: Use of Tumor Markers in Bladder Cancer (95 kb)

3I: Tumor Markers in Pancreatic Ductal Adenocarcinoma (174 kb)

3J: Use of Tumor Markers in Cervical Cancer (81 kb)

3K: Use of Tumor Markers in Monoclonal Gammopathies (69 kb)

3L: Use of Tumor Markers in Malignant Melanoma (253 kb)

3M: Use of Tumor Markers in Parathyroid Gland Adenomas and Carcinomas (106 kb)

3N: Use of Tumor Markers in Neoplasms of the Dispersed Neuroendocrine System (126 kb)

3O: Use of Tumor Markers in Differentiated Epithelial Thyroid Carcinoma (82 kb)

3P: Use of Tumor Markers in Lung Cancer (203 kb)

Section 4

4A: Use of Microarrays in Cancer Diagnostics (73 kb)

4B: Use of MALDI-TOF Mass Spectometry Profiling to Diagnose Cancer (120 kb)